CN1157374C - 非晶形阿托伐他汀钙的制备方法 - Google Patents

非晶形阿托伐他汀钙的制备方法 Download PDF

Info

Publication number
CN1157374C
CN1157374C CNB008144583A CN00814458A CN1157374C CN 1157374 C CN1157374 C CN 1157374C CN B008144583 A CNB008144583 A CN B008144583A CN 00814458 A CN00814458 A CN 00814458A CN 1157374 C CN1157374 C CN 1157374C
Authority
CN
China
Prior art keywords
atorvastatin calcium
amorphous atorvastatin
amorphous
atorvastatin
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008144583A
Other languages
English (en)
Chinese (zh)
Other versions
CN1379760A (zh
Inventor
Z
Z·戈里弗
ɼ�����
P·考特纳吉
J·巴考茨
G·斯米格
L·巴拉茨
I·多曼
¿
Z·拉德凯
P·塞雷斯
Z·圣特克拉里
F·巴瑟
���ɶ��ؼ�����
G·维里克兹科纳多纳斯
K·纳吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Egis Pharmaceuticals PLC
Original Assignee
Egis Pharmaceuticals PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egis Pharmaceuticals PLC filed Critical Egis Pharmaceuticals PLC
Publication of CN1379760A publication Critical patent/CN1379760A/zh
Application granted granted Critical
Publication of CN1157374C publication Critical patent/CN1157374C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNB008144583A 1999-10-18 2000-10-17 非晶形阿托伐他汀钙的制备方法 Expired - Fee Related CN1157374C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9903634A HU226640B1 (en) 1999-10-18 1999-10-18 Process for producing amorphous atorvastatin calcium salt
HUP9903634 1999-10-18

Publications (2)

Publication Number Publication Date
CN1379760A CN1379760A (zh) 2002-11-13
CN1157374C true CN1157374C (zh) 2004-07-14

Family

ID=90014241

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008144583A Expired - Fee Related CN1157374C (zh) 1999-10-18 2000-10-17 非晶形阿托伐他汀钙的制备方法

Country Status (17)

Country Link
EP (1) EP1235800B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003512354A (cg-RX-API-DMAC7.html)
KR (1) KR100664353B1 (cg-RX-API-DMAC7.html)
CN (1) CN1157374C (cg-RX-API-DMAC7.html)
AT (1) ATE345327T1 (cg-RX-API-DMAC7.html)
AU (1) AU1166301A (cg-RX-API-DMAC7.html)
CA (1) CA2388018C (cg-RX-API-DMAC7.html)
CZ (1) CZ300071B6 (cg-RX-API-DMAC7.html)
DE (1) DE60031882T2 (cg-RX-API-DMAC7.html)
HR (1) HRP20020334B1 (cg-RX-API-DMAC7.html)
HU (1) HU226640B1 (cg-RX-API-DMAC7.html)
PL (1) PL354604A1 (cg-RX-API-DMAC7.html)
RS (1) RS50473B (cg-RX-API-DMAC7.html)
RU (1) RU2255932C2 (cg-RX-API-DMAC7.html)
SK (1) SK286861B6 (cg-RX-API-DMAC7.html)
UA (1) UA72777C2 (cg-RX-API-DMAC7.html)
WO (1) WO2001028999A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
DE10135493A1 (de) * 2001-07-20 2003-01-30 Jobst Krauskopf Pharmazeutische Zusammensetzung zur Behandlung von Hypercholesterinämie
AU2002255479B2 (en) 2001-07-30 2008-09-11 Dr. Reddy's Laboratories Ltd. Crystalline forms VI and VII of atorvastatin clacium
HUP0500074A3 (en) * 2002-03-18 2005-07-28 Biocon Ltd Bangalore Amorphous hmg-coa reductase inhibitors of desired particle size and process for producing them
RU2309141C2 (ru) * 2002-03-18 2007-10-27 Байокон Лимитид АМОРФНЫЕ ИНГИБИТОРЫ ГМГ-КоА-РЕДУКТАЗЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
WO2003099785A1 (en) * 2002-05-28 2003-12-04 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
HU227041B1 (en) * 2003-03-24 2010-05-28 Richter Gedeon Nyrt Process for the synthesis of amorphous atorvastatin calcium
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
CZ298382B6 (cs) * 2004-03-10 2007-09-12 Zentiva, A. S. Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace
WO2005092852A1 (en) 2004-03-17 2005-10-06 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
CN1960972A (zh) * 2004-04-16 2007-05-09 辉瑞产品公司 用于形成无定形阿托伐它汀钙的方法
CN1692906A (zh) * 2004-04-30 2005-11-09 鲁南制药集团股份有限公司 治疗高血脂症的组合物
CA2649054A1 (en) 2004-05-05 2005-11-10 Pfizer Products Inc. Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
CA2573969C (en) * 2004-07-16 2014-02-04 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
JP2008506764A (ja) 2004-07-20 2008-03-06 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態
WO2006037125A1 (en) 2004-09-28 2006-04-06 Teva Pharmaceutical Industries Ltd. Process for preparing forms of atorvastatin calcium substantially free of impurities
CN101039906A (zh) * 2004-10-18 2007-09-19 特瓦制药工业有限公司 通过将盐溶解于有机溶剂并除去该溶剂来制备无定形阿托伐他汀半钙的方法，所述有机溶剂为醇和酮和 /或酯的混合物
WO2006046109A1 (en) 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
ATE466840T1 (de) 2005-11-21 2010-05-15 Warner Lambert Co Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
KR100833439B1 (ko) * 2007-01-02 2008-05-29 씨제이제일제당 (주) 비결정형 아토르바스타틴 칼슘의 개선된 제조방법
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
CN103274985B (zh) * 2010-12-03 2016-03-09 上海科州药物研发有限公司 一种阿托伐他汀氨基酸盐

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
ATE123020T1 (de) * 1990-05-11 1995-06-15 American Cyanamid Co N-acylierte arylpyrrole als insektizide, akarizide, nematizide und molluskizide wirkstoffe.
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
WO1998012200A1 (en) * 1996-09-20 1998-03-26 Meiji Seika Kaisha Ltd. A crystalline substance of cefditoren pivoxyl and the production of the same

Also Published As

Publication number Publication date
HUP9903634A3 (en) 2002-01-28
RU2255932C2 (ru) 2005-07-10
RS50473B (sr) 2010-03-02
HU226640B1 (en) 2009-05-28
YU28302A (sh) 2005-06-10
CA2388018C (en) 2008-04-08
ATE345327T1 (de) 2006-12-15
EP1235800A1 (en) 2002-09-04
CA2388018A1 (en) 2001-04-26
CN1379760A (zh) 2002-11-13
HUP9903634D0 (en) 1999-12-28
DE60031882T2 (de) 2007-07-05
SK5192002A3 (en) 2002-11-06
WO2001028999A1 (en) 2001-04-26
KR20020063166A (ko) 2002-08-01
AU1166301A (en) 2001-04-30
HUP9903634A2 (hu) 2001-12-28
DE60031882D1 (de) 2006-12-28
HK1050199A1 (en) 2003-06-13
HRP20020334A2 (en) 2004-02-29
HRP20020334B1 (hr) 2007-12-31
JP2003512354A (ja) 2003-04-02
PL354604A1 (en) 2004-01-26
SK286861B6 (sk) 2009-06-05
UA72777C2 (en) 2005-04-15
KR100664353B1 (ko) 2007-01-02
EP1235800B1 (en) 2006-11-15
CZ20021256A3 (cs) 2002-08-14
CZ300071B6 (cs) 2009-01-21

Similar Documents

Publication Publication Date Title
CN1157374C (zh) 非晶形阿托伐他汀钙的制备方法
CN101679218B (zh) 晶体米诺环素碱及其制备方法
CN1196679C (zh) 无定形阿托伐斯汀钙的制备方法
CN1942439B (zh) 无定形形式的阿托伐他汀钙的制备方法
US6646133B1 (en) Process for the preparation of amorphous atorvastatin calcium
WO2007099552A2 (en) Novel crystalline form of atovastatin hemi-magnesium
EP1761489A1 (en) Crystalline form of atorvastatin hemi calcium
CN1812971A (zh) 培哚普利特丁胺的新晶形
WO2002102777A2 (en) NOVEL CRYSTALLINE FORMS OF 4-[4-[4-(HYDROXYDIPHENYLMETHYL)-1-PIPERINDINYL]-1-HYDROXYBUTYL]-α, α-DIMETHYLBENZENE ACETIC ACID AND ITS HYDROCHLORIDE
WO2008010087A2 (en) Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
JP2008510798A (ja) 非晶質アトルバスタチンカルシウムのための方法
WO2007096903A2 (en) New crystalline form of atorvastatin hemi-calcium
CN1946687B (zh) 阿托伐他汀叔丁基酯的多晶型物及其作为中间体在制备阿托伐他汀中的应用
HK1050199B (en) Process for the preparation of amorphous atorvastatin calcium
US20040063969A1 (en) Process for the preparation of amorphous atorvastatin calcium
WO2011131601A1 (en) Production of atorvastatin low in lactone impurities
CN101657419A (zh) 吡咯基庚酸衍生物的新晶型
WO2009063476A1 (en) A crystalline form of atorvastatin hemi magnesium salt and a process thereof
CN103108863A (zh) 低醚杂质的阿托伐他汀的制备
WO2010019435A2 (en) Solid states of atorvastatin potassium
US20050165242A1 (en) Process for the preparation of amorphous atorvastatin calcium
WO2007039784A2 (en) A novel crystalline polymorph of fluvastatin sodium and process for preparing it

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1050199

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040714

Termination date: 20091117